Entrada Therapeutics (TRDA) Cash from Financing Activities (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Cash from Financing Activities of $100000.0 for Q1 2026, down 71.43% year-over-year from $350000.0 in Q1 2025, and down 47.92% quarter-over-quarter from $192000.0 in Q4 2025.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 71.43% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $637000.0 (down 99.38% YoY), while the FY2025 annual figure was $887000.0, down 99.14% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $100000.0, down from $192000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $101.4 million in Q2 2024, with the low at -$11000.0 in Q3 2024.
- The 5-year median for Cash from Financing Activities is $337000.0 (2025), against an average of $7.4 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities jumped 38972.0% in 2023, then tumbled 102.99% in 2024.
- Entrada Therapeutics' Cash from Financing Activities stood at $358000.0 in 2022, then jumped by 92.74% to $690000.0 in 2023, then surged by 103.19% to $1.4 million in 2024, then tumbled by 86.31% to $192000.0 in 2025, then slumped by 47.92% to $100000.0 in 2026.
- Business Quant data shows TRDA's Cash from Financing Activities at $100000.0 in Q1 2026, $192000.0 in Q4 2025, and $8000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Entrada Therapeutics | 296.82 Mn | 296.82 Mn | - | 350,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 350,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 192,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 337,000.00 |
| Mar 31, 2025 | 350,000.00 |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | -11,000.00 |
| Jun 30, 2024 | 101.37 Mn |
| Mar 31, 2024 | 206,000.00 |
| Dec 31, 2023 | 690,000.00 |
| Sep 30, 2023 | 368,000.00 |
| Jun 30, 2023 | 443,000.00 |
| Mar 31, 2023 | 19.54 Mn |
| Dec 31, 2022 | 358,000.00 |
| Sep 30, 2022 | 60,000.00 |
| Jun 30, 2022 | 11,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | 190.76 Mn |
| Sep 30, 2021 | 106,000.00 |